Dilon Technologies
received FDA approval and launched MarginProbe 2, a next-generation radiofrequency-spectroscopy probe for intraoperative breast-tumor margin assessment in breast-conserving surgery, continuing the MarginProbe technology line through a pivotal trial for the upgraded device.
- Country
- United States
Commercial
MarginProbe 2
Coverage
| CN | EU | US | |
|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Intraoperative molecular diagnostics | diagnostics-medtech | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.